List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Tyrosine Protein Kinase JAK3 - Overview
Tyrosine Protein Kinase JAK3 - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Tyrosine Protein Kinase JAK3 - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Tyrosine Protein Kinase JAK3 - Companies Involved in Therapeutics Development
Tyrosine Protein Kinase JAK3 - Drug Profiles
Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Dormant Products
Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Discontinued Products
Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indications, 2022
Number of Products under Development by Indications, 2022 (Contd..1)
Number of Products under Development by Indications, 2022 (Contd..2)
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022 (Contd..2)
Products under Development by Companies, 2022 (Contd..3)
Products under Development by Companies, 2022 (Contd..4)
Products under Development by Companies, 2022 (Contd..5)
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by Aclaris Therapeutics Inc, 2022
Pipeline by Alexion Pharmaceuticals Inc, 2022
Pipeline by Arrien Pharmaceuticals LLC, 2022
Pipeline by Astellas Pharma Inc, 2022
Pipeline by Bristol-Myers Squibb Co, 2022
Pipeline by Celon Pharma SA, 2022
Pipeline by Clevexel Pharma SA, 2022
Pipeline by Daewoong Pharmaceutical Co Ltd, 2022
Pipeline by Guangdong Zhongsheng Pharmaceutical Co Ltd, 2022
Pipeline by Impetis Biosciences Ltd, 2022
Pipeline by Japan Tobacco Inc, 2022
Pipeline by KBP Biosciences Co Ltd, 2022
Pipeline by Kinaset Therapeutics Inc, 2022
Pipeline by MedAvail Holdings Inc, 2022
Pipeline by Merck & Co Inc, 2022
Pipeline by Oncostellae SL, 2022
Pipeline by Pfizer Inc, 2022
Pipeline by Shenzhen Chipscreen Biosciences Co Ltd, 2022
Pipeline by Simcere Pharmaceutical Group Ltd, 2022
Pipeline by Theravance Biopharma Inc, 2022
Dormant Products, 2022
Dormant Products, 2022 (Contd..1)
Dormant Products, 2022 (Contd..2)
Dormant Products, 2022 (Contd..3)
Discontinued Products, 2022

List of Figures
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Stage and Molecule Type, 2022

Companies Mentioned
• Aclaris Therapeutics Inc
• Alexion Pharmaceuticals Inc
• Arrien Pharmaceuticals LLC
• Astellas Pharma Inc
• Bristol-Myers Squibb Co
• Celon Pharma SA
• Clevexel Pharma SA
• Daewoong Pharmaceutical Co Ltd
• Guangdong Zhongsheng Pharmaceutical Co Ltd
• Impetis Biosciences Ltd
• Japan Tobacco Inc
• KBP Biosciences Co Ltd
• Kinaset Therapeutics Inc
• MedAvail Holdings Inc
• Merck & Co Inc
• Oncostellae SL
• Pfizer Inc
• Shenzhen Chipscreen Biosciences Co Ltd
• Simcere Pharmaceutical Group Ltd
• Theravance Biopharma Inc